Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Biodistribution and Radiation Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Healthy Volunteers
NCT07774650Phase 1Recruiting
- Sponsor
- Ratio Therapeutics
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of granzyme-B targeted [64Cu]-labeled PET radiotracer (2 arms), sponsored by Ratio Therapeutics. Primary endpoints: Maximum concentration of radiation in the blood at 24 hours, Time to maximum concentration in the blood at 24 hours and 6 more. Started Jul 2026; status: recruiting.
02
Drugs
granzyme-B targeted [64Cu]-labeled PET radiotracer
Beyond the preview
Go deeper on NCT07774650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774650.